Limits...
Remarkable regression of an osteolytic lesion of large cell lung cancer treated with zoledronic Acid: a case report.

Kawai S, Yamaura G, Yasuda K, Suzuki T - Case Rep Oncol (2012)

Bottom Line: Zoledronic acid suppresses osteoclastic changes and reduces the risk of cancer-induced skeletal-related events.Moreover, it has been reported to have antitumor effects.However, it was markedly regressed after zoledronic acid monotherapy, and the patient's symptoms almost disappeared.

View Article: PubMed Central - PubMed

Affiliation: Sendai Medical Center, Sendai, Japan.

ABSTRACT
Zoledronic acid suppresses osteoclastic changes and reduces the risk of cancer-induced skeletal-related events. Moreover, it has been reported to have antitumor effects. The authors here present a case of a male patient with large cell lung cancer who had an osteolytic lesion in the thoracic vertebrae. The cancer was moderately sensitive to radiation therapy but barely sensitive to chemotherapy with cytotoxic agents. However, it was markedly regressed after zoledronic acid monotherapy, and the patient's symptoms almost disappeared. This remarkable response of large cell lung cancer to zoledronic acid monotherapy is rare.

No MeSH data available.


Related in: MedlinePlus

a Enhanced CT examination performed on the patient's first visit. Arrows indicate the tumor. b A sagittal image of the osteolytic lesion of the thoracic vertebrae shown by MRI on the patient's first visit.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3369252&req=5

Figure 1: a Enhanced CT examination performed on the patient's first visit. Arrows indicate the tumor. b A sagittal image of the osteolytic lesion of the thoracic vertebrae shown by MRI on the patient's first visit.

Mentions: For further evaluation, enhanced computed tomography (CT) and magnetic resonance imaging (MRI) were performed. Radiography revealed a heterogeneously enhanced mass in the left superior mediastinum that infiltrated the left side of the first to third thoracic vertebrae (fig. 1). Only the carcinoembryonic antigen (CEA) tumor marker was elevated at 190.2 ng/ml (normal value <3.4).


Remarkable regression of an osteolytic lesion of large cell lung cancer treated with zoledronic Acid: a case report.

Kawai S, Yamaura G, Yasuda K, Suzuki T - Case Rep Oncol (2012)

a Enhanced CT examination performed on the patient's first visit. Arrows indicate the tumor. b A sagittal image of the osteolytic lesion of the thoracic vertebrae shown by MRI on the patient's first visit.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3369252&req=5

Figure 1: a Enhanced CT examination performed on the patient's first visit. Arrows indicate the tumor. b A sagittal image of the osteolytic lesion of the thoracic vertebrae shown by MRI on the patient's first visit.
Mentions: For further evaluation, enhanced computed tomography (CT) and magnetic resonance imaging (MRI) were performed. Radiography revealed a heterogeneously enhanced mass in the left superior mediastinum that infiltrated the left side of the first to third thoracic vertebrae (fig. 1). Only the carcinoembryonic antigen (CEA) tumor marker was elevated at 190.2 ng/ml (normal value <3.4).

Bottom Line: Zoledronic acid suppresses osteoclastic changes and reduces the risk of cancer-induced skeletal-related events.Moreover, it has been reported to have antitumor effects.However, it was markedly regressed after zoledronic acid monotherapy, and the patient's symptoms almost disappeared.

View Article: PubMed Central - PubMed

Affiliation: Sendai Medical Center, Sendai, Japan.

ABSTRACT
Zoledronic acid suppresses osteoclastic changes and reduces the risk of cancer-induced skeletal-related events. Moreover, it has been reported to have antitumor effects. The authors here present a case of a male patient with large cell lung cancer who had an osteolytic lesion in the thoracic vertebrae. The cancer was moderately sensitive to radiation therapy but barely sensitive to chemotherapy with cytotoxic agents. However, it was markedly regressed after zoledronic acid monotherapy, and the patient's symptoms almost disappeared. This remarkable response of large cell lung cancer to zoledronic acid monotherapy is rare.

No MeSH data available.


Related in: MedlinePlus